Rak Activators include a variety of compounds that indirectly enhance the activity of Rak, a tyrosine kinase involved in multiple cellular signaling pathways. These activators primarily function by inhibiting other kinases or signaling pathways, thus potentially increasing the reliance on Rak for certain cellular functions. For instance, broad-spectrum kinase inhibitors like Staurosporine, and specific inhibitors such as PP 2 (Src family kinase inhibitor) and Dasatinib (Bcr-Abl and Src kinase inhibitor), indirectly enhance Rak's activity by reducing the activity of competing kinases. This inhibition could lead to a compensatory increase in Rak-mediated signaling, highlighting its role in cellular communication and regulation. Similarly, Genistein and Erlotinib, Free Base, by inhibiting other tyrosine kinases and EGFR respectively, may enhance Rak's function in cell signaling pathways, particularly those driven by tyrosine kinase activity.
Further contributing to the regulation of Rak activity are compounds like Lapatinib, Sorafenib, U0126, Tyrphostin B42, LY 294002, SP600125, and PF-00562271. These inhibitors target various kinases and signaling molecules, including EGFR, HER2, Raf, VEGFR, PDGFR, MEK, JAK2, PI3K, JNK, and FAK. Inhibition of these pathways potentially shifts the balance of cellular signaling towards Rak-dependent pathways. For example, Lapatinib's inhibition of EGFR and HER2, and Sorafenib's action against Raf and receptor tyrosine kinases, could lead to increased reliance on Rak signaling in processes like cell growth and survival. U0126 and Tyrphostin B42, by targeting the MAPK/ERK and JAK2 pathways, respectively, might enhance Rak's role in alternate signaling routes. LY 294002's impact on PI3K/Akt signaling and SP600125's inhibition of JNK could also shift cellular responses to favor Rak-mediated mechanisms. PF-00562271, as a FAK inhibitor, suggests a potential increase in Rak signaling in adhesion-related pathways. Collectively, these Rak Activators demonstrate the intricate network of signaling pathways in cells and the adaptability of Rak's function in response to the inhibition of various kinases and signaling molecules, underscoring its versatility and importance in cellular signaling and regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, indirectly enhances Rak activity by inhibiting competing tyrosine kinases, thereby potentially increasing Rak’s relative activity in signal transduction pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, indirectly activates Rak by inhibiting other tyrosine kinases, thereby possibly enhancing Rak's function in cell signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib, Free Base, an EGFR inhibitor, indirectly enhances Rak activity by inhibiting EGFR tyrosine kinase, potentially leading to increased Rak activity in EGFR-driven pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, an inhibitor of EGFR and HER2, indirectly activates Rak by reducing competition from these receptors, possibly enhancing Rak's role in signal transduction. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly enhances Rak activity by inhibiting several kinases including Raf, VEGFR, and PDGFR, potentially leading to increased Rak signaling. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42, a JAK2 inhibitor, indirectly enhances Rak activity by inhibiting JAK2, potentially shifting the signaling balance towards Rak-mediated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002, a PI3K inhibitor, indirectly activates Rak by altering PI3K/Akt signaling, potentially leading to increased Rak activity in alternate signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly enhances Rak activity by inhibiting JNK signaling, potentially increasing the role of Rak in cellular stress responses. | ||||||